Clinical Trials Logo
  1. Home
  2. Agitation,Psychomotor
  3. NCT02504450

Outcomes of Antipsychotic Medication Used in the Emergency Department — OAMED  

Agitation,Psychomotor Clinical Trial

Official title:
Outcomes of Antipsychotic Medication Use in the Emergency Department: A Retrospective Comparison Study

Clinical Trial Summary

To review records of patients treated with antipsychotics (including Adasuve, Geodon, Haldol) in order to evaluate outcomes.

Clinical Trial Description

A retrospective chart review will be performed for all patients presenting to the ED with agitation and subsequently given antipsychotic therapy for treatment. Identification of patients will be through chart review of patients presenting with agitation. Data to be recorded include patient age, gender, medical history, time of presentation, time of treatment, co morbidities, use of restraint, time to disposition and patient outcome. Inclusion criteria include all patients over age 18 presenting to the ED with agitation and treated with antipsychotics. No patients will be knowingly excluded from analysis. We will compare resulting outcomes of patients treated for agitation to see if Adasuve is superior to other commonly prescribed antipsychotics through its rate of discharge home and overall time in the emergency department. ;

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02504450
Study type Observational
Source Advocate Health Care
Contact
Status Completed
Phase N/A
Start date April 2015
Completion date March 2016
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03110900 - Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation Phase 4
Completed NCT05272501 - CAlming Touch for People With Agitation or Other Behavioural Symptoms of DEMentia - A Randomized Feasibility Trial N/A
Completed NCT06041646 - Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder Phase 4
Completed NCT06217146 - A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia. N/A
Recruiting NCT05543681 - IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's Phase 2
Recruiting NCT03513549 - Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder
Active, not recruiting NCT05658510 - Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) Phase 3
Not yet recruiting NCT05612711 - Dronabinol for Agitation in Dementia Crossover Trial Phase 2
Recruiting NCT04957238 - Physical Restraints in Intensive Care Unit Patients N/A
Completed NCT03208452 - The Effect of Intraoperative Magnesium Sulfate Infusion on the Occurrence of Emergence Agitation Phase 4
Terminated NCT03899506 - Olanzapine Versus Midazolam for Agitation
Completed NCT03211897 - Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation N/A
Recruiting NCT05783505 - A Multicomponent Intervention Program to Prevent and Reduce ICU Agitation and Physical Restraint Use N/A
Completed NCT04053426 - Agitation Follow up After Introduction of a New Patient Care Algorithm
Completed NCT03226522 - Addressing Dementia Via Agitation-Centered Evaluation Phase 2/Phase 3
Recruiting NCT03926520 - Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD) N/A
Recruiting NCT04075435 - Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia Early Phase 1
Completed NCT04276883 - Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder Phase 3
Completed NCT04797715 - Assessing Clinical Outcomes in Alzheimer's Disease Agitation Phase 3
Completed NCT04251910 - Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia Phase 1/Phase 2